Lupus & antiphospholipid syndrome
Significant hypomethylation of MMP9 gene promoter in patients with systemic lupus erythematosus
Authors' conclusion
The results of this study highlight the application of MMP9 methylation level in PBMCs of SLE patients as a diagnostic biomarker.
Study context
- Population
- Iranian systemic lupus erythematosus (SLE) patients and healthy controls; MMP9 and TNFAIP3 promoter methylation in peripheral blood mononuclear cells (PBMCs)
- Participants
- 80 vs 77
- Comparison
- SLE patients vs healthy controls
- SLEn = 80
- Healthy controlsn = 77reference
- Outcome
- Methylation level of MMP9 and TNFAIP3 promoters in PBMCs
Main finding
As reported in the abstract
Promoter methylation in PBMCs
- SLE vs Healthy controls: P < 0.001
- SLE vs Healthy controls: P = 0.167
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| MMP9 methylation by renal involvementRenal involvement vs No renal involvement | Renal involvement 42.07 ± 25.73 · No renal involvement 56.74 ± 29.71 | P = 0.007 |
| Diagnostic power of MMP9 promoter methylation for SLE (ROC) | MMP9 methylation AUC 0.839 · 95% CI 0.781-0.911 |
Correlations of MMP9 methylation
- Negatively correlated with creatinine and anti-dsDNA concentration
- Positively correlated with C3 and C4 levels
Original publication
Significant hypomethylation of MMP9 gene promoter in patients with systemic lupus erythematosus. Lupus. Published 23 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →